Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Existential Crisis in Canada Could Lead To More Pricing Pressure

Executive Summary

Worried about its relevance to payers, Canada's drug price regulator is consulting on how it should modernize its guidelines. The result could be more pressure on regulated prices.

You may also be interested in...

Canada Plans To Force Firms To Disclose Confidential Pricing Deals

Companies operating in Canada could face pharmacoeconomic evaluations to decide if drugs are over-priced as well as a requirement to disclose information that could impair the confidentiality of pricing agreements.

Canada Plans Drug Price Reductions By Changing Reference Country List

Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.

Canada's Price Negotiators On Where Firms Go Wrong

If your company wants to sell its products on Canada's publicly funded drug plans, then it will likely have to do business with the pan-Canadian Pharmaceutical Alliance. This is the body that negotiates drug prices for provincial and territorial drug plans and which has ensured that product listing agreements have become a prerequisite for securing drug funding across the Canadian market. The pCPA's Brad Alyward, from Nova Scotia's Department for Health and Wellness, and Sherry O'Quinn*, from the Ontario Public Drug Programs Division, spoke to Scrip about the perils of trying to charge too high a price and the future of evidence generation-based agreements.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts